Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
63
Frequently Asked Questions
What is Market Cap of Shield Therapeutics plc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Shield Therapeutics plc market cap is $86.54M.
What is the 52-week high for Shield Therapeutics plc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Shield Therapeutics plc 52 week high is $0.1169 as of October 10, 2025.
What is the 52-week low for Shield Therapeutics plc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Shield Therapeutics plc 52 week low is $0.0331 as of October 10, 2025.
What is Shield Therapeutics plc stock price today?
Shield Therapeutics plc stock price today is $0.0975.
What was Shield Therapeutics plc stock price yesterday?
Shield Therapeutics plc stock price yesterday was $0.1016.
What is the PE ratio of Shield Therapeutics plc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Shield Therapeutics plc’s P/E ratio is -4.05.
What is the Price-to-Book ratio of Shield Therapeutics plc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Shield Therapeutics plc P/B ratio is -6.8373.
What is the 50-day moving average of Shield Therapeutics plc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Shield Therapeutics plc 50-day moving average is $0.0868.
How many employess does Shield Therapeutics plc has?